GRAND: The German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 223-231

  Hadji, P ^a   Claus, V ^b   Ziller, V ^a   Intorcia, M ^c   Kostev, K ^b   Steinle, T ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b IQVIA   (United States)

^c AMGEN INC   (United States)

^d Amgen Research GmbH   (Germany)

Author keywords

Compliance; Fracture rate; Oral bisphosphonates; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; ARTICLE; DATA BASE; FEMALE; FRAGILITY FRACTURE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; EPIDEMIOLOGIC METHODS; FEMALE; GERMANY; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES;

EID: 84857358150     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1535-z     Document Type: Article

References (45)

1. Kanis JA, Reginster JY (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women - what is the current message for clinical practice? Pol Arch Med Wewn 118:538-540
2. Cooper C (1999) Epidemiology of osteoporosis. Osteoporos Int 9 (Suppl 2):S2-S8 (Pubitemid 29231749)
3. Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(Suppl 1):4-9
4. Cole ZA, Dennison EM, Cooper C (2008) Osteoporosis epidemiology update. Curr Rheumatol Rep 10:92-96
5. Glüer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Blenk T, Armbrecht G, Stewart A, Clowes J, Thomasius FE, Kolta S (2004) Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res 19:782-793 (Pubitemid 41094390)
6. Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporos Int 18:77-84 (Pubitemid 44885498)
7. Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges AJ, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez VA, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T, Naves-Diaz M, Pols HA, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O'Neill TW (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 13:565-571 (Pubitemid 34790629)
8. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995 (Pubitemid 34105967)
9. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
10. Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 4:304-324
11. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249-1256 (Pubitemid 44085576)
12. Cotte FE, Mercier F, De PG (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 30:2410-2422
13. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435-1441
14. Penning-van Beest FJA, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
15. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
16. Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271-277 (Pubitemid 46233172)
17. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97
18. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686-1694 (Pubitemid 44838898)
19. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031 (Pubitemid 47019996)
20. Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N (2008) Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 10:207-213 (Pubitemid 351649619)
21. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861 (Pubitemid 40911458)
22. Bartl R, Gotte S, Hadji P, Hammerschmidt T (2006) Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr 131:1257-1262 (Pubitemid 44173951)
23. Höer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Häussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25-30
24. Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617-626
25. DIMDI (2007) ICD-10-GM version 2008. Deutsches Institut für Medizinische Dokumentation und Information, Cologne
26. DGEpi (2010) Leitlinien Und Empfehlungen Zur Sicherung Von Guter Epidemiologischer Praxis. Deutsche Gesellschaft für Epidemiologie, Hannover
27. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122: S3-S13
28. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728-740
29. Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303-2315
30. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
31. Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437-443 (Pubitemid 351466455)
32. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928 (Pubitemid 44498580)
33. Col N, Fanale JE, Kronholm P (1990) The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 150:841-845 (Pubitemid 20122061)
34. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177:575-580 (Pubitemid 47437054)
35. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S (2009) Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a populationbased study. Osteoporos Int 20:1571-1581
36. Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA Study. Osteoporos Int 17:664-671
37. Reginster JY (2006) Adherence and persistence: impact on outcomes and health care resources. Bone 38(Suppl 2):S18-S21
38. Schousboe JT, Dowd BE, Davison ML, Kane RL (2010) Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899-1909
39. Haynes RB, McKibbon KA, Kanani R (1996) Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 348:383-386 (Pubitemid 26261515)
40. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev:CD000011
41. Castelo-Branco C, Cortés X, Ferrer M (2010) Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric 13:578-584
42. Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMCWomens Health 10:26
43. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-155
44. Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21-26
45. Ojeda-Bruno S, Naranjo A, Francisco-Hernández F, Erausquin C, Rúa-Figueroa I, Quevedo JC, Rodríguez-Lozano C (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int. doi:10.1007/s00198-010-1414-z